The Editorial direction and decision regarding manuscripts published, are managed by the Editor-in-Chief and Editorial Board and all material is peer reviewed by two reviewers. Editor-in-chief and the Editorial Board are independent of the publisher and are not employees of the publisher.


EDITORS

Mitchell A.H. Levine MD,

BSc (McGill), MSc (McMaster), MD(Calgary) , FRCPC, FISPE, FACP Professor, Department of Clinical Epidemiology & Biostatistics Joint Member, Department of Medicine, Division of Clinical Pharmacology Director, Centre for Evaluation of Medicines Active Staff, St. Joseph's Hospital Consultant, Ontario Drug Benefit Program Member, Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, Health Canada Vice-Chair, Patented Medicine Prices Review Board

Dr. Mitchell Levine received his medical degree from the University of Calgary, which was followed by postgraduate medical training in Internal Medicine and in Clinical Pharmacology at the University of Toronto. He received an MSc in Clinical Epidemiology from McMaster University. Dr. Levine is a Professor at McMaster University in the Department of Health Research Methods, Evidence and Impact and in the Department of Medicine, Division of Clinical Pharmacology. He is the Director for the Program for Assessment of Technology in Health (P.A.T.H) and the Director for the Centre for Evaluation of Medicines (both affiliated with St. Joseph?s Healthcare Hamilton and McMaster University). Dr. Levine is a practicing consultant physician in the fields of Internal Medicine and Clinical Pharmacology at St. Joseph's Healthcare Hamilton. Dr. Levine is the Vice-Chair of the Patented Medicine Prices Review Board of Canada. He also serves as an advisor to governments on issues relating to drug safety, efficacy and pharmaco-economics. He is a consultant to the Drug Benefits Program of the Ontario Ministry of Health and Long Term Care and to Health Canada. His academic activities include assessing prescription drug use in the community and developing methods to obtain maximum value from drug therapy resources. He is the Editor for both the Canadian Journal of General Internal Medicine and the Journal of Population Therapeutics and Clinical Pharmacology, and is an Associate Editor for ACP Journal Club and Evidence-Based Medicine

Sarah Burgess,

Sarah Burgess is a clinical pharmacist currently integrated into a collaborative primary care clinic in rural Nova Scotia. In addition to her clinical practice, Sarah lectures for the undergraduate pharmacy program at the College of Pharmacy, Dalhousie University and has been involved in co-coordinating and teaching the Critical Appraisal Series course which focuses on critically evaluating the medical literature and applying evidence to clinical practice and decision making.

Sarah is also affiliated with the Drug Assessment Working Group for the Therapeutics Initiative, University of British Columbia which analyzes the scientific evidence on the effectiveness and safety of drug therapies used in Canada. Sarah?s research interests include pharmacy practice, optimal medication use and deprescribing.

Sarah graduated from the College of Pharmacy at Dalhousie University (Halifax, NS) in 2010 and then completed a hospital pharmacy residency in London, Ontario. From 2011 to 2013, Sarah was a clinical pharmacist on the Internal Medicine service at London Health Sciences Centre. In 2015, Sarah completed a 2-year post-graduate Doctor of Pharmacy at the University of British Columbia.

Folefac Aminkeng,

Dr.Folefac Aminkeng is a research fellow at the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) and the Department of Medical Genetics of the University of British Columbia. Folefac obtained his master's degree and PhD in Medical Sciences from the VrijeUniversiteit Brussel in Belgium and joined the CPNDS as a postdoctoral fellow in 2011. His research interests have focused on the ?pharmacogenomics of adverse drug reactions? and ?pharmacogenomicpharmacoethnicity in clinical therapeutics?. He has made significant contributions to these fields including the identification of a gene that is involved in cardiomyopathy and congestive heart failure after cancer treatment (Aminkeng F et al, Nature Genetics. 2015 Sep; 47(9):1079-84.). He is the recipient of a number of fellowships including the Canadian Institutes of Health Research, Michael Smith Foundation for Health Research and the British Columbia Children Hospital Research Institute Bertram Hoffmeister Postdoctoral Fellowships. He has also been recognized for a distinguish academic and scientific career through a number of career awards including the 2015 Canadian Society of Pharmacology and Therapeutics Boehringer-Ingelheim Postdoctoral Award, the 2016 British Columbia Children?s Hospital Research Institute award for outstanding achievement by a postdoctoral fellow, the 2015 Golden Helix Top Prize and the 2015 Canadian Society of Pharmacology and Therapeutics Publication Award. He currently serves on theCanadian Society of Pharmacology and TherapeuticsScientific Program Committee and is a member of several academic societies including the American Association of Pharmaceutical Scientists, British Pharmacological Society, European Society of Pharmacogenomics and Personalized Therapy, Canadian Association for Population Therapeutics, American Society of Human Genetics and Canadian Society for Pharmaceutical Sciences.

Guy Chouinard,

Guy Chouinard MD, M.Sc. (Pharmacol) F.R.C.P.(C), F.A.P.A. was a Professor of Psychiatry and Medicine at McGill University and Professor of Psychiatry at the University of Montreal. He was an Invited Professor at the Faculties of Biology and Medicine at the University of Lausanne in Switzerland, and University of Paris-Sud XI in France.

He is Director Emeritus of the Psychotic Disorders External Services at the McGill University Health Center at McGill University, Founding Director and Director Emeritus of the Royal College Accredited Program in Clinical Pharmacology and Toxicology at McGill University, Founding Director and Director Emeritus of the Clinical Psychopharmacology Unit, McGill University Health Center at McGill University.

He is a Founding Member of the Specialty of Clinical Pharmacology, Royal College of Physicians and Surgeons of Canada, and a Founding Member of the Canadian College of Neuropsychopharmacology.

Dr. Chouinard?s psychopharmacological research has significantly contributed to the progress of pharmacological treatments of schizophrenia, bipolar disorder, major depression and anxiety disorders. He conducted pioneering and innovative studies of benzodiazepine and non-benzodiazepine antianxiety/hypnotics, antiepileptics, atypical antipsychotics, and SSRI/SNRI antidepressants. Among his contributions are his studies on alprazolam, clonazepam, fluoxetine, sertraline, venlafaxine, tryptophan, magnesium, rubidium, risperidone, clozapine, valproate and gabapentin.

He also specialized in drug-induced disorders, studying tardive dyskinesia and drug-induced movement disorders. He developed a valid and reliable clinical scale, the Extrapyramidal Symtom Rating Scale, to predict and detect the occurrence of drug-induced movement disorders, which is used world-wide in clinical research. He discovered syndromes such rebound anxiety, rebound panic, persistent postwithdrawal disorders and supersensitivity psychosis. Recently, he proposed a new classification of SSRI/SNRI withdrawal.

He has published more than 300 refereed reports in scientific journals, and several book chapters on psychopharmacological treatments and psychiatric semiology. In addition, he has presented more than 600 communications at scientific meetings, lecturing as a guest speaker more than 300 times.

He sits on the editorial board of the journal Psychotherapy and Psychosomatics. He has been an active Member of the American College of Neuropsychopharmacology (ACNP). He is an Honorary Founding Fellow of the Canadian College of Neuropsychopharmacology. You could add your Journal previously CJCP

He is Researcher Emeritus, University Mental Health Institute of Montreal, Research Center Fernand Seguin, University of Montreal, Canada

Dr. Irena Nulman,

Dr. Nulman is a Professor of Pediatrics, Pharmacology, and Pharmacy. She is the Program Director of Fellowship Training in Clinical Pharmacology at the University of Toronto, Staff Pharmacologist at the Division of Clinical Pharmacology and Toxicology at the Hospital for Sick Children. She received her medical degree from Ternopol Medical School in Ukraine. She received a Certificate in Neurology in Israel, specializing in Neuropharmacology.She completed her training in Reproductive Toxicology at the Hospital for Sick Children in Toronto. Dr. Nulman joined the faculty in 2004 and received the FRCPC in Neurology in 2008. She is the Director of the Fetal Alcohol Syndrome Clinic at the Hospital for Sick Children. She holds a Diploma in Clinical Epidemiology and a PhD in research methodology from University of Toronto, Canada.

Dr. Nulman is an Associate Scientist at theResearch Institute. She is an expert in behavioural teratology of psychotropic drugs (anticonvulsant, antidepressant, antipsychotic, and alcohol). In collaboration with psychology division she established the Behavioural Teratology Program and actively participated in the development of the Canadian National Guidelines in diagnosing Fetal Alcohol Spectrum Disorder.

She contributes extensively to behavioral teratology research and is the author of ground-breaking publications in this field.

Colleen Maxwell,

Dr. Colleen Maxwell is a Professor with the Schools of Pharmacy and Public Health & Health Systems, University of Waterloo, an Adjunct Scientist with the Institute for Clinical Evaluative Sciences (ICES), and an Adjunct Professor with Community Health Sciences, University of Calgary. She is a senior health services researcher with expertise in aging, frailty, continuing care and pharmacoepidemiology. Her research interests include the quality of care and pharmacotherapy of older vulnerable populations across the care continuum ? particularly those with dementia, depression and related disorders. A particular focus within these areas is the investigation of different approaches to screen for (and grade) levels of frailty among older adults with the goal of using this information for improving geriatric pharmacotherapy and outcomes. Dr. Maxwell is a past Board Member of the International Society for Pharmacoepidemiology, Canadian Association for Population Therapeutics and a current Board Member of the Canadian Society for Epidemiology and Biostatistics and the PROPEL Centre for Population Health Impact (University of Waterloo).

Micheline Piquette-Miller,

Micheline Piquette-Miller is a Professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto and an Associate Editor of Clinical Pharmacology & Therapeutics. Dr. Piquette-Miller completed a BSc. in Pharmacy and PhD in Pharmacokinetics at the University of Alberta and aPostdoctoral Fellowship at the University of California in San Francisco. Her research primarily focuses on understanding the regulation of drug transport proteins and how this impacts drug disposition. She has published over 95 research articlesand has been the recipient of numerous prestigious national and international research awards including ASCPT?s Leon Goldberg Young Investigator Award, RX&D/CIHR Research Career Award; CSPT?s PfiaskyYoung Investigator Award, University of Alberta?s Horizon Award, AFPC?s Pfizer Research Career Award and most recently FDA?sORISE Fellowship Award.She has also served positions on the executive councils of ASCPT andCSPS, and is a past-president of CSPT.

Bhushan M. Kapur,

I graduated with a D.Phil. from the University of Basel, Switzerland in 1967. My doctoral thesis supervisor was Prof. Dr. T. Reichstein, (Nobel Laureate 1956). I was the Director of Laboratories at the Addiction Research Foundation (ARF) from 1971 to May 1995. The toxicology laboratory at ARF was responsible for providing a 24hour/7days emergency identification of drugs including alcohol for almost 80 hospitals in the metropolitan of Toronto. From May 1995 to December 2015, I was with the Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children in Toronto. I joined this program as a scientist and a consultant in toxicology after leaving ARF. In June 2000, I was appointed as a consultant and in Laboratory Medicine in the Department of Clinical Pathology, Sunnybrook Health Science Centre and in 2008 a Research Associate in the Sunnybrook Research Institute. From August 2001 to November 2005, I was responsible for the direction of the toxicology laboratory at the St. Michael?s Hospital in Toronto. I was a consultant in toxicology with Canadian Medical Laboratories from 1997 to 2013. My research interests have been in the biochemical changes in the alcohol and drug using population and pharmacokinetics in the opiate dependent patient. I have 298 publications and presentations (111 peer reviewed publications and 187 presentations at scientific conferences). Over the years, I have been recipient of grants from various organizations: CIHR, NIH, MRC, NIAA, WHO, Can Found for Fetal Alcohol Research and Alva Foundation Grant in Neonatal and Newborn health. As a scientist I have developed ?Point of Care? devices for Ethanol, Acetaminophen, Salicylate and methanol to be used in the emergency room or clinical laboratory in triaging these poisonings. My other credits include coauthoring a book titledAlcohol and the Identification of Alcoholics, invention and patent of an alcohol dipstick, a computer software program CBAC: Computerized Blood Alcohol Calculator, and book chapters on drugs of abuse. I am Associate Professor in the Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto. I am also Chartered Chemist and Fellow of The Royal Society of Chemistry (UK); Fellow of Academy of Clinical Biochemistry (USA) and Canadian Academy of Clinical Biochemistry (CAN). As Inspector for Forensic Urine Drug Testing, American College of Pathologists I have participated in inspections of laboratories requesting certification to do Work Place Drugs of Abuse testing. I have attended ILO (International Labour Organization, UN, Geneva) sponsored Tripartite (Governments, Employers and Labour) meetings in Geneva and Oslo as WHO?s expert in Workplace Drug Testing.

Dr. Mina Tadrous,

Dr. Mina Tadrous is currently a Research Associate with the Ontario Drug Policy Research Network (ODPRN), a cross-provincial research team based at St. Michael?s Hospital focused on providing timely, high-quality, relevant research to decision makers. Mina?s research interests lie in drug policy research and the post-marketing surveillance of safety and effectiveness of medications used to treat chronic diseases.

He completed a PhD in pharmacoepidemiology at the University of Toronto and previously completed a Masters in Health Outcomes and Policy Research at the University of Tennessee, and a Doctor of Pharmacy at Albany College of Pharmacy. He also completed a pharmacy residency in Drug Information and health Outcomes at the University of Tennessee and St. Jude Children?s Research Hospital. He is a practicing pharmacist who has worked in a variety of clinical settings. He is also currently a fellow at the Institute for Clinical Evaluative Sciences (ICES)

Lisa Dolovich,

Dr. Lisa Dolovich is the Ontario College of Pharmacists Professor in Pharmacy Practice at the Leslie Dan Faculty of Pharmacy at the University of Toronto and a Professor in the Department of Family Medicine (and cross appointed to the Departments of Clinical Epidemiology and Biostatistics and Medicine) at McMaster University. She is also a Scientist with the Centre for Evaluation of Medicines at St. Joseph?s Healthcare, Hamilton, an Associate Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto and an Adjunct Associate Clinical Professor in the School of Pharmacy University of Waterloo. She is an expert in the implementation and evaluation of complex interventions in community based primary health care including pharmacy practice, implementation science methods, interdisciplinary healthcare team integration, and research on medication prescribing and use.

David Blackburn,

David Blackburn is a Professor and Chair in Patient Adherence at the College of Pharmacy and Nutrition, University of Saskatchewan. He is also the Director of the Saskatchewan Drug Utilization and Outcomes Research Team (SDUORT). His research program is focused on patient adherence, drug utilization, health outcomes, and chronic disease management. He has extensive experience in the use of the Saskatchewan?s health-administrative databases for studying the use of prescriptions and their influence on health outcomes. He continues to teach undergraduate pharmacy students and trains Master?s and PhD level candidates in the College of Pharmacy & Nutrition.

Indexed In

SCImago Journal & Country Rank

Journal Flyer

Societies

Indexed In